CTOR — Citius Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- $178.88m
- $182.68m
Annual cashflow statement for Citius Oncology, fiscal year end - September 30th, millions except per share.
2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|
| Period Length: | — | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | |
| Standards: | — | USG | USG |
| Status: | fx Preliminary | Final | Final |
| Net Income/Starting Line | — | -12.7 | -21.1 |
| Deferred Taxes | |||
| Non-Cash Items | — | 1.97 | 7.5 |
| Other Non-Cash Items | |||
| Changes in Working Capital | — | 10.2 | 13.2 |
| Change in Inventories | |||
| Change in Prepaid Expenses | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | — | 0 | 0.126 |
| Other Investing Cash Flow Items | — | 0 | -5 |
| Other Investing Cash Flow | |||
| Cash from Investing Activities | — | 0 | -5 |
| Financing Cash Flow Items | — | 0 | 1.07 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | — | 0 | 4.87 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | — | 0 | 0 |